Mucosal vaccination: onward and upward

References

• Elphick DA, Mahida YR. Paneth cells: their role in innate immunity and inflammatory disease. Gut. 2005;54(12):1802–1809. doi: 10.1136/gut.2005.068601
   PubMed Web of Science ®Google Scholar
• Cesta MF. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol. 2006;34(5):599–608. doi: 10.1080/01926230600865531
   PubMed Web of Science ®Google Scholar
• Pavot V, Rochereau N, Genin C, et al. New insights in mucosal vaccine development. Vaccine. 2012;30(2):142–154. doi: 10.1016/j.vaccine.2011.11.003
   PubMed Web of Science ®Google Scholar
• Kurashima Y, Kiyono H. Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing. Annu Rev Immunol. 2017;35(1):119–147. doi: 10.1146/annurev-immunol-051116-052424
   PubMed Web of Science ®Google Scholar
• Kim DY, Sato A, Fukuyama S, et al. The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J Immunol. 2011;186(7):4253–4262. doi: 10.4049/jimmunol.0903794
   PubMed Web of Science ®Google Scholar
• Anggraeni R, Ana ID, Wihadmadyatami H. Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants. Clin Exp Vaccine Res. 2022;11(3):235–248. doi: 10.7774/cevr.2022.11.3.235
   PubMed Web of Science ®Google Scholar
• Kaetzel CS, Robinson JK, Chintalacharuvu KR, et al. The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc Natl Acad Sci U S A. 1991;88(19):8796–8800. doi: 10.1073/pnas.88.19.8796
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11(4 Suppl):S45–53. doi: 10.1038/nm1213
   PubMed Web of Science ®Google Scholar
• Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008;8(6):421–434. doi: 10.1038/nri2322
   PubMed Web of Science ®Google Scholar
• Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol. 2003;3(10):822–829. doi: 10.1038/nri1203
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Debes GF, Johnston B, et al. Targeting T cell responses by selective chemokine receptor expression. Semin Immunol. 2003;15(5):277–286. doi: 10.1016/j.smim.2003.08.005
   PubMed Web of Science ®Google Scholar
• Kaetzel CS. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev. 2005;206(1):83–99. doi: 10.1111/j.0105-2896.2005.00278.x
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol. 2012;354:1–18. doi: 10.1007/82_2010_112
   PubMed Web of Science ®Google Scholar
• Svennerholm AM, Lundgren A, Leach S, et al. Mucosal immune responses against an oral enterotoxigenic Escherichia coli vaccine evaluated in clinical trials. J Infect Dis. 2021;224(12 Suppl 2):S821–S828. doi: 10.1093/infdis/jiab475
   PubMedGoogle Scholar
• Johansson M, Schon K, Ward M, et al. Genital tract infection with chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin a response. Infect Immun. 1997;65(3):1032–1044. doi: 10.1128/IAI.65.3.1032-1044.1997
   PubMed Web of Science ®Google Scholar
• Ermak TH, Giannasca PJ, Nichols R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med. 1998;188(12):2277–2288. doi: 10.1084/jem.188.12.2277
   PubMed Web of Science ®Google Scholar
• Lamichhane A, Azegamia T, Kiyonoa H. The mucosal immune system for vaccine development. Vaccine. 2014;32(49):6711–6723. doi: 10.1016/j.vaccine.2014.08.089
   PubMed Web of Science ®Google Scholar
• Kiyono H, Azegami T. The mucosal immune system: from dentistry to vaccine development. Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(8):423–439. doi: 10.2183/pjab.91.423
   PubMed Web of Science ®Google Scholar
• Kiyono H, Kweon MN, Hiroi T, et al. The mucosal immune system: from specialized immune defense to inflammation and allergy. Acta Odontol Scand. 2001;59(3):145–153. doi: 10.1080/000163501750266738
   PubMed Web of Science ®Google Scholar
• Fujkuyama Y, Tokuhara D, Kataoka K, et al. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012;11(3):367–379. doi: 10.1586/erv.11.196
   PubMed Web of Science ®Google Scholar
• Boyaka PN. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J Immunol. 2017;199(1):9–16. doi: 10.4049/jimmunol.1601775
   PubMed Web of Science ®Google Scholar
• Flemming A. ‘Prime and spike’ induces mucosal immunity and reduces SARS-CoV-2 transmission. Nat Rev Immunol. 2022;22(12):718. doi: 10.1038/s41577-022-00804-2
   Web of Science ®Google Scholar
• Tang J, Zeng C, Cox TM, et al. Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination. Sci Immunol. 2022;7(76):eadd4853. doi: 10.1126/sciimmunol.add4853
   PubMed Web of Science ®Google Scholar
• Kraehenbuhl JP, Neutra MR. Mucosal vaccines: where do we stand? Curr Top Med Chem. 2013;13(20):2609–2628. doi: 10.2174/15680266113136660186
   PubMed Web of Science ®Google Scholar
• Moldoveanu Z, Clements ML, Prince SJ, et al. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine. 1995;13(11):1006–1012. doi: 10.1016/0264-410x(95)00016-t
   PubMed Web of Science ®Google Scholar
• Russell MW, Mestecky J. Mucosal immunity: the missing link in comprehending SARS-CoV-2 infection and transmission. Front Immunol. 2022;13:957107. doi: 10.3389/fimmu.2022.957107
   PubMed Web of Science ®Google Scholar
• Lue C, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol. 1988;140(11):3793–3800. doi: 10.4049/jimmunol.140.11.3793
   PubMed Web of Science ®Google Scholar
• Xu H, Cai L, Hufnagel S, et al. Intranasal vaccine: factors to consider in research and development. Int J Pharm. 2021;609:121180. doi: 10.1016/j.ijpharm.2021.121180
   PubMedGoogle Scholar
• Brokstad KA, Eriksson JC, Cox RJ, et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis. 2002;185(7):878–884. doi: 10.1086/339710
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Ichinohe T, Ainai A, et al. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther Clin Risk Manag. 2009;5(1):125–132. doi: 10.2147/tcrm.s3297
   PubMedGoogle Scholar
• Jang YH, Byun YH, Lee YJ, et al. Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza a viruses. J Virol. 2012;86(10):5953–5958. doi: 10.1128/JVI.07149-11
   PubMed Web of Science ®Google Scholar
• Ainai A, Tamura S, Suzuki T, et al. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults. Hum Vaccin Immunother. 2013;9(9):1962–1970. doi: 10.4161/hv.25458
   PubMed Web of Science ®Google Scholar
• Azegami T, Yuki Y, Kiyono H. Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol. 2014;26(9):517–528. doi: 10.1093/intimm/dxu063
   PubMed Web of Science ®Google Scholar
• Burgess TH, Murray CK, Bavaro MF, et al. Self-administration of intranasal influenza vaccine: immunogenicity and volunteer acceptance. Vaccine. 2015;33(32):3894–3899. doi: 10.1016/j.vaccine.2015.06.061
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Wu X. The safety and effectiveness of self-administration of intranasal live attenuated influenza vaccine in adults. Vaccine. 2013;31(6):857–860. doi: 10.1016/j.vaccine.2012.12.028
   PubMed Web of Science ®Google Scholar
• Couch RB, Atmar RL, Keitel WA, et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine. 2012;31(1):190–195. doi: 10.1016/j.vaccine.2012.10.065
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Fry AM, et al. Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4) - United States, 2018-19 influenza season. MMWR Morb Mortal Wkly Rep. 2018;67(22):643–645. doi: 10.15585/mmwr.mm6722a5
   PubMed Web of Science ®Google Scholar
• Konopka-Anstadt JL, Campagnoli R, Vincent A, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5(1):26. doi: 10.1038/s41541-020-0176-7
   PubMed Web of Science ®Google Scholar
• McNeil MM, Paradowska-Stankiewicz I, Miller ER, et al. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the vaccine adverse event reporting system (VAERS). Vaccine. 2019;37(44):6760–6767. United States, October 2011-July 2018 doi: 10.1016/j.vaccine.2019.08.087
   PubMed Web of Science ®Google Scholar
• Pawinski R, Debrus S, Delem A, et al. Rotarix in developing countries: paving the way for inclusion in national childhood immunization programs in Africa. J Infect Dis. 2010;202(Suppl 1):S80–86. doi: 10.1086/653547
   PubMedGoogle Scholar
• van Hoek AJ, Ngama M, Ismail A, et al. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines. PLoS One. 2012;7(10):e47511. doi: 10.1371/journal.pone.0047511
   PubMed Web of Science ®Google Scholar
• Yang B, Foley S. First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune((R)). BJU Int. 2018;121(2):289–292. doi: 10.1111/bju.14067
   PubMed Web of Science ®Google Scholar
• Lorenzo-Gomez MF, Padilla-Fernandez B, Garcia-Criado FJ, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J. 2013;24(1):127–134. doi: 10.1007/s00192-012-1853-5
   PubMed Web of Science ®Google Scholar
• Haas NL, Haas MRC, Gregory C. A case report of anaphylaxis to typhoid vaccine live oral Ty21a (Vivotif). J Travel Med. 2017;24(5):5. doi: 10.1093/jtm/tax022
   Web of Science ®Google Scholar
• Pennington SH, Ferreira DM, Caamano-Gutierrez E, et al. Nonspecific effects of oral vaccination with live-attenuated salmonella typhi strain Ty21a. Sci Adv. 2019;5(2):eaau6849. doi: 10.1126/sciadv.aau6849
   PubMed Web of Science ®Google Scholar
• Freedman DO. Re-born in the USA: another cholera vaccine for travellers. Travel Med Infect Dis. 2016;14(4):295–296. doi: 10.1016/j.tmaid.2016.07.008
   PubMed Web of Science ®Google Scholar
• Baik YO, Choi SK, Olveda RM, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (euvichol vs Shanchol) in the Philippines. Vaccine. 2015;33(46):6360–6365. doi: 10.1016/j.vaccine.2015.08.075
   PubMed Web of Science ®Google Scholar
• van Splunter M, van Hoffen E, Floris-Vollenbroek EG, et al. Oral cholera vaccination promotes homing of IgA(+) memory B cells to the large intestine and the respiratory tract. Mucosal Immunol. 2018;11(4):1254–1264. doi: 10.1038/s41385-018-0006-7
   PubMed Web of Science ®Google Scholar
• Moyle PM, Toth I. Modern subunit vaccines: development, components, and research opportunities. ChemMedchem. 2013;8(3):360–376. doi: 10.1002/cmdc.201200487
   PubMed Web of Science ®Google Scholar
• Favre D, Viret JF. Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. Vaccine. 2006;24(18):3856–3864. doi: 10.1016/j.vaccine.2005.07.018
   PubMed Web of Science ®Google Scholar
• Kiyono H, Yuki Y, Nakahashi-Ouchida R, et al. Mucosal vaccines: wisdom from now and then. Int Immunol. 2021;33(12):767–774. doi: 10.1093/intimm/dxab056
   PubMed Web of Science ®Google Scholar
• Yuki Y, Nojima M, Kashima K, et al. Oral MucoRice-CTB vaccine is safe and immunogenic in healthy US adults. Vaccine. 2022;40(24):3372–3379. doi: 10.1016/j.vaccine.2022.04.051
   PubMed Web of Science ®Google Scholar
• Garg NK, Mangal S, Khambete H, et al. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv Formul. 2010;4(2):114–128. doi: 10.2174/187221110791185015
   PubMedGoogle Scholar
• Nakahashi-Ouchida R, Yuki Y, Kiyono H. Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases. Hum Vaccin Immunother. 2018;14(9):2189–2193. doi: 10.1080/21645515.2018.1461298
   PubMed Web of Science ®Google Scholar
• Kang H, Yan M, Yu Q, et al. Characteristics of nasal-associated lymphoid tissue (NALT) and nasal absorption capacity in chicken. PLoS One. 2013;8(12):e84097. doi: 10.1371/journal.pone.0084097
   PubMed Web of Science ®Google Scholar
• Kakutani H, Kondoh M, Fukasaka M, et al. Mucosal vaccination using claudin-4-targeting. Biomaterials. 2010;31(20):5463–5471. doi: 10.1016/j.biomaterials.2010.03.047
   PubMed Web of Science ®Google Scholar
• Zaman M, Chandrudu S, Toth I. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res. 2013;3(1):100–109. doi: 10.1007/s13346-012-0085-z
   PubMed Web of Science ®Google Scholar
• Yuki Y, Nojima M, Hosono O, et al. Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial. Lancet Microbe. 2021;2(9):e429–e440. doi: 10.1016/S2666-5247(20)30196-8
   PubMedGoogle Scholar
• Shen Y, Hu Y, Qiu L. Nano-vesicles based on phospholipid-like amphiphilic polyphosphazenes to orally deliver ovalbumin antigen for evoking anti-tumor immune response. Acta Biomater. 2020;106:267–277. doi: 10.1016/j.actbio.2020.02.012
   PubMed Web of Science ®Google Scholar
• Moran HBT, Turley JL, Andersson M, et al. Immunomodulatory properties of chitosan polymers. Biomaterials. 2018;184:1–9. doi: 10.1016/j.biomaterials.2018.08.054
   PubMed Web of Science ®Google Scholar
• Carroll EC, Jin L, Mori A, et al. The vaccine adjuvant chitosan promotes cellular immunity via DNA sensor cGAS-STING-Dependent induction of type I interferons. Immunity. 2016;44(3):597–608. doi: 10.1016/j.immuni.2016.02.004
   PubMed Web of Science ®Google Scholar
• Shen Y, Qiu L. Effective oral delivery of gp100 plasmid vaccine against metastatic melanoma through multi-faceted blending-by-blending nanogels. Nanomedicine. 2019;22:102114. doi: 10.1016/j.nano.2019.102114
   PubMed Web of Science ®Google Scholar
• Verma AK, Sharma S, Gupta P, et al. Vitamin B12 grafted layer-by-layer liposomes bearing HBsAg facilitate oral immunization: effect of modulated biomechanical properties. Mol Pharm. 2016;13(7):2531–2542. doi: 10.1021/acs.molpharmaceut.6b00274
   PubMed Web of Science ®Google Scholar
• Yang M, Lai SK, Wang YY, et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew Chem Int Ed Engl. 2011;50(11):2597–2600. doi: 10.1002/anie.201006849
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang J, Zhu X, et al. Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery. J Control Release. 2016;222:67–77. doi: 10.1016/j.jconrel.2015.12.008
   PubMed Web of Science ®Google Scholar
• Kimoto T, Kim H, Sakai S, et al. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice. Vaccine. 2019;37(4):612–622. doi: 10.1016/j.vaccine.2018.12.002
   PubMed Web of Science ®Google Scholar
• Clements JD, Norton EB, Papasian CJ. The mucosal vaccine adjuvant LT(R192G/L211A) or dmLT. mSphere. 2018;3(4). doi: 10.1128/mSphere.00215-18
   PubMed Web of Science ®Google Scholar
• Norton EB, Bauer DL, Weldon WC, et al. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909–1915. doi: 10.1016/j.vaccine.2015.02.069
   PubMed Web of Science ®Google Scholar
• Chen CH, Chen CC, Wang WB, et al. Intranasal immunization with Zika virus envelope domain III-Flagellin fusion protein elicits systemic and mucosal immune responses and protection against subcutaneous and intravaginal virus challenges. Pharmaceutics. 2022;14(5):1014. doi: 10.3390/pharmaceutics14051014
   PubMed Web of Science ®Google Scholar
• Zhang T, Chen X, Liu H, et al. A rationally designed flagellin-L2 fusion protein induced serum and mucosal neutralizing antibodies against multiple HPV types. Vaccine. 2019;37(30):4022–4030. doi: 10.1016/j.vaccine.2019.06.002
   PubMed Web of Science ®Google Scholar
• Zhao B, Yang J, He B, et al. A safe and effective mucosal RSV vaccine in mice consisting of RSV phosphoprotein and flagellin variant. Cell Rep. 2021;36(3):109401. doi: 10.1016/j.celrep.2021.109401
   PubMed Web of Science ®Google Scholar
• Lin SF, Jiang PL, Tsai JS, et al. Surface assembly of poly(I: C) on polyethyleneimine-modified gelatin nanoparticles as immunostimulatory carriers for mucosal antigen delivery. J Biomed Mater Res B Appl Biomater. 2019;107(4):1228–1237. doi: 10.1002/jbm.b.34215
   PubMed Web of Science ®Google Scholar
• Meijlink MA, Chua YC, Chan STS, et al. 6’’-modified alpha-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria. RSC Chem Biol. 2022;3(5):551–560. doi: 10.1039/d1cb00251a
   PubMedGoogle Scholar
• Ahmed M, Smith DM, Hamouda T, et al. A novel nanoemulsion vaccine induces mucosal interleukin-17 responses and confers protection upon mycobacterium tuberculosis challenge in mice. Vaccine. 2017;35(37):4983–4989. doi: 10.1016/j.vaccine.2017.07.073
   PubMed Web of Science ®Google Scholar
• Bakshi S, Sanz Garcia R, Van der Weken H, et al. Evaluating single-domain antibodies as carriers for targeted vaccine delivery to the small intestinal epithelium. J Control Release. 2020;321:416–429. doi: 10.1016/j.jconrel.2020.01.033
   PubMed Web of Science ®Google Scholar
• Baert K, de Geest, BG, de Rycke R, et al. Beta-glucan microparticles targeted to epithelial APN as oral antigen delivery system. J Control Release. 2015;220(Pt A):149–159. doi: 10.1016/j.jconrel.2015.10.025
   PubMedGoogle Scholar
• Sun Y, Qian J, Xu X, et al. Dendritic cell-targeted recombinantLactobacilli induce DC activation and elicit specific immune responses against G57 genotype of avian H9N2 influenza virus infection. Vet Microbiol. 2018;223:9–20. doi: 10.1016/j.vetmic.2018.07.009
   PubMed Web of Science ®Google Scholar
• Kataoka K, Fujihashi K, Oma K, et al. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun. 2011;79(7):2819–2828. doi: 10.1128/IAI.01360-10
   PubMed Web of Science ®Google Scholar
• Kim SH, Seo KW, Kim J, et al. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol. 2010;185(10):5787–5795. doi: 10.4049/jimmunol.0903184
   PubMed Web of Science ®Google Scholar
• Liebowitz D, Lindbloom JD, Brandl JR, et al. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial. Lancet Infect Dis. 2015;15(9):1041–1048. doi: 10.1016/S1473-3099(15)00266-2
   PubMed Web of Science ®Google Scholar
• Liebowitz D, Gottlieb K, Kolhatkar NS, et al. Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. Lancet Infect Dis. 2020;20(4):435–444. doi: 10.1016/S1473-3099(19)30584-5
   PubMed Web of Science ®Google Scholar
• Joyce C, Scallan CD, Mateo R, et al. Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats. Vaccine. 2018;36(29):4265–4277. doi: 10.1016/j.vaccine.2018.05.112
   PubMed Web of Science ®Google Scholar
• Kim L, Martinez CJ, Hodgson KA, et al. Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule. Sci Rep. 2016;6(1):37295. doi: 10.1038/srep37295
   PubMedGoogle Scholar
• Scallan CD, Tingley DW, Lindbloom JD, et al. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013;20(1):85–94. doi: 10.1128/CVI.00552-12
   PubMed Web of Science ®Google Scholar
• Yurina V, Rahayu Adianingsih O, Widodo N. Oral and intranasal immunization with food-grade recombinant Lactococcus lactis expressing high conserved region of SARS-CoV-2 spike protein triggers mice’s immunity responses. Vaccine: X. 2023;13:100265. doi: 10.1016/j.jvacx.2023.100265
   PubMedGoogle Scholar
• Mohseni AH, Razavilar V, Keyvani H, et al. Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice. J Med Virol. 2019;91(2):296–307. doi: 10.1002/jmv.25303
   PubMed Web of Science ®Google Scholar
• Blanchett S, Tsai CJ, Sandford S, et al. Intranasal immunization with Ag85B peptide 25 displayed on Lactococcus lactis using the PilVax platform induces antigen-specific B- and T-cell responses. Immunol Cell Biol. 2021;99(7):767–781. doi: 10.1111/imcb.12462
   PubMed Web of Science ®Google Scholar
• Clow F, Peterken K, Pearson V, et al. PilVax, a novel Lactococcus lactis-based mucosal vaccine platform, stimulates systemic and mucosal immune responses to staphylococcus aureus. Immunol Cell Biol. 2020;98(5):369–381. doi: 10.1111/imcb.12325
   PubMed Web of Science ®Google Scholar
• Wagachchi D, Tsai JC, Chalmers C, et al. PilVax - a novel peptide delivery platform for the development of mucosal vaccines. Sci Rep. 2018;8(1):2555. doi: 10.1038/s41598-018-20863-7
   PubMedGoogle Scholar
• Jia Z, Ma C, Yang X, et al. Oral immunization of recombinant Lactococcus lactis and Enterococcus faecalis expressing dendritic cell targeting peptide and Hexon protein of Fowl adenovirus 4 induces protective immunity against Homologous infection. Front Vet Sci. 2021;8:632218. doi: 10.3389/fvets.2021.632218
   PubMed Web of Science ®Google Scholar
• Tvinnereim AR, Hamilton SE, Harty JT. CD8(+)-T-cell response to secreted and nonsecreted antigens delivered by recombinant listeria monocytogenes during secondary infection. Infect Immun. 2002;70(1):153–162. doi: 10.1128/IAI.70.1.153-162.2002
   PubMed Web of Science ®Google Scholar
• Chen G, Dai Y, Chen J, et al. Oral delivery of the Sj23LHD-GST antigen by salmonella typhimurium type III secretion system protects against schistosoma japonicum infection in mice. PLoS Negl Trop Dis. 2011;5(9):e1313. doi: 10.1371/journal.pntd.0001313
   PubMed Web of Science ®Google Scholar
• Gould VMW, Francis JN, Anderson KJ, et al. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front Microbiol. 2017;8:900. doi: 10.3389/fmicb.2017.00900
   PubMed Web of Science ®Google Scholar
• Dong C, Wang Y, Gonzalez GX, et al. Intranasal vaccination with influenza HA/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains. Proc Natl Acad Sci U S A. 2021;118(19). doi: 10.1073/pnas.2024998118
   Web of Science ®Google Scholar
• Varma DM, Batty CJ, Stiepel RT, et al. Development of an intranasal gel for the delivery of a broadly acting subunit influenza vaccine. ACS Biomater Sci Eng. 2022;8(4):1573–1582. doi: 10.1021/acsbiomaterials.2c00015
   PubMed Web of Science ®Google Scholar
• Lim JME, Tan AT, Le Bert N, et al. SARS-CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad specificity. J Exp Med. 2022;219(10). doi: 10.1084/jem.20220780
   Web of Science ®Google Scholar
• Pilapitiya D, Wheatley AK, Tan HX. Mucosal vaccines for SARS-CoV-2: triumph of hope over experience. EBioMedicine. 2023;92:104585. doi: 10.1016/j.ebiom.2023.104585
   PubMed Web of Science ®Google Scholar
• Pitcovski J, Gruzdev N, Abzach A, et al. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine. Vaccine. 2022;40(8):1098–1107. doi: 10.1016/j.vaccine.2022.01.025
   PubMed Web of Science ®Google Scholar
• Wu S, Huang J, Zhang Z, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCov) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21(12):1654–1664. doi: 10.1016/S1473-3099(21)00396-0
   PubMed Web of Science ®Google Scholar
• Lockhart A, Mucida D, Parsa R. Immunity to enteric viruses. Immunity. 2022;55(5):800–818. doi: 10.1016/j.immuni.2022.04.007
   PubMed Web of Science ®Google Scholar
• Yao Y, Jeyanathan M, Haddadi S, et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell. 2018;175(6):1634–1650, e1617. doi: 10.1016/j.cell.2018.09.042
   PubMed Web of Science ®Google Scholar
• D’Agostino MR, Lai R, Afkhami S, et al. Airway macrophages mediate mucosal vaccine-induced trained innate immunity against mycobacterium tuberculosis in early stages of infection. J Immunol. 2020;205(10):2750–2762. doi: 10.4049/jimmunol.2000532
   PubMed Web of Science ®Google Scholar
• Xing Z, Afkhami S, Bavananthasivam J, et al. Innate immune memory of tissue-resident macrophages and trained innate immunity: re-vamping vaccine concept and strategies. J Leukocyte Biol. 2020;108(3):825–834. doi: 10.1002/JLB.4MR0220-446R
   PubMed Web of Science ®Google Scholar
• Neutra MR, Pringault E, Kraehenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol. 1996;14(1):275–300. doi: 10.1146/annurev.immunol.14.1.275
   PubMedGoogle Scholar
• van Ginkel, FW, Jackson RJ, Yuki Y, et al. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol. 2000;165(9):4778–4782. doi: 10.4049/jimmunol.165.9.4778
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med. 2004;350(9):896–903. doi: 10.1056/NEJMoa030595
   PubMed Web of Science ®Google Scholar
• Kraan H, Vrieling H, Czerkinsky C, et al. Buccal and sublingual vaccine delivery. J Control Release. 2014;190:580–592. doi: 10.1016/j.jconrel.2014.05.060
   PubMed Web of Science ®Google Scholar
• Czerkinsky C, Cuburu N, Kweon MN, et al. Sublingual vaccination. Hum Vaccin. 2011;7(1):110–114. doi: 10.4161/hv.7.1.13739
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. Am J Respir Crit Care Med. 2011;183(12):1595–1604. doi: 10.1164/rccm.201011-1783OC
   PubMed Web of Science ®Google Scholar
• Seo KY, Han SJ, Cha HR, et al. Eye mucosa: an efficient vaccine delivery route for inducing protective immunity. J Immunol. 2010;185(6):3610–3619. doi: 10.4049/jimmunol.1000680
   PubMed Web of Science ®Google Scholar
• Nagatake T, Fukuyama S, Kim DY, et al. Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity. J Exp Med. 2009;206(11):2351–2364. doi: 10.1084/jem.20091436
   PubMed Web of Science ®Google Scholar
• Oya Y, Kimura S, Nakamura Y, et al. Characterization of M cells in tear duct-associated lymphoid tissue of mice: a potential role in Immunosurveillance on the ocular surface. Front Immunol. 2021;12:779709. doi: 10.3389/fimmu.2021.779709
   PubMed Web of Science ®Google Scholar
• Kim ED, Han SJ, Byun YH, et al. Inactivated eyedrop influenza vaccine adjuvanted with poly(I: C) is safe and effective for inducing protective systemic and mucosal immunity. PLoS One. 2015;10(9):e0137608. doi: 10.1371/journal.pone.0137608
   PubMed Web of Science ®Google Scholar
• Yoon S, Kim ED, Song MS, et al. Eyedrop vaccination induced systemic and mucosal immunity against influenza virus in ferrets. PLoS One. 2016;11(6):e0157634. doi: 10.1371/journal.pone.0157634
   PubMed Web of Science ®Google Scholar
• Kim J, Kim ED, Shin HS, et al. Effectiveness and safety of injectable human papilloma virus vaccine administered as eyedrops. Vaccine. 2023;41(1):92–100. doi: 10.1016/j.vaccine.2022.09.070
   PubMed Web of Science ®Google Scholar
• Mestecky J, Moldoveanu Z, Russell MW. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol. 2005;53(5):208–214. doi: 10.1111/j.1600-0897.2005.00267.x
   PubMed Web of Science ®Google Scholar
• Lavelle EC, Ward RW. Mucosal vaccines - fortifying the frontiers. Nat Rev Immunol. 2022;22(4):236–250. doi: 10.1038/s41577-021-00583-2
   PubMed Web of Science ®Google Scholar
• Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol. 2012;12(8):592–605. doi: 10.1038/nri3251
   PubMed Web of Science ®Google Scholar
• Gordon SN, Kines RC, Kutsyna G, et al. Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol. 2012;188(2):714–723. doi: 10.4049/jimmunol.1101404
   PubMed Web of Science ®Google Scholar
• Hopkins WJ, Elkahwaji J, Beierle LM, et al. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol. 2007;177(4):1349–1353. quiz 1591. doi: 10.1016/j.juro.2006.11.093
   PubMed Web of Science ®Google Scholar
• Kantele A, Hakkinen M, Moldoveanu Z, et al. Differences in immune responses induced by oral and rectal immunizations with salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun. 1998;66(12):5630–5635. doi: 10.1128/IAI.66.12.5630-5635.1998
   PubMed Web of Science ®Google Scholar
• Johansson EL, Bergquist C, Edebo A, et al. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine. 2004;22(8):984–990. doi: 10.1016/j.vaccine.2003.09.002
   PubMed Web of Science ®Google Scholar
• Quiding M, Nordstrom I, Kilander A, et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest. 1991;88(1):143–148. doi: 10.1172/JCI115270
   PubMed Web of Science ®Google Scholar
• Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res. 1997;16(2):187–201. doi: 10.1007/BF02786362
   PubMed Web of Science ®Google Scholar
• Johansson EL, Wassen L, Holmgren J, et al. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun. 2001;69(12):7481–7486. doi: 10.1128/IAI.69.12.7481-7486.2001
   PubMed Web of Science ®Google Scholar
• Stary G, Olive A, Radovic-Moreno AF, et al. VACCINES. A mucosal vaccine against chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015;348(6241):aaa8205. doi: 10.1126/science.aaa8205
   PubMed Web of Science ®Google Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng. 2012;14(1):17–46. doi: 10.1146/annurev-bioeng-071811-150054
   PubMedGoogle Scholar
• Mestecky J, Russell MW, Elson CO. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol. 2007;179(9):5633–5638. doi: 10.4049/jimmunol.179.9.5633
   PubMed Web of Science ®Google Scholar
• Ilan Y. Oral immune regulation toward disease-associated antigens: results of phase I clinical trials in Crohn’s disease and chronic hepatitis. Ann N Y Acad Sci. 2004;1029(1):286–298. doi: 10.1196/annals.1309.059
   PubMedGoogle Scholar
• Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387–391. doi: 10.1038/7385
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu J, Wang J, et al. Targeted delivery of antigen to intestinal dendritic cells induces oral tolerance and prevents autoimmune diabetes in NOD mice. Diabetologia. 2018;61(6):1384–1396. doi: 10.1007/s00125-018-4593-3
   PubMed Web of Science ®Google Scholar
• Li Y, Jin L, Chen T. The effects of secretory IgA in the mucosal immune system. Biomed Res Int. 2020;2020:2032057. doi: 10.1155/2020/2032057
   PubMed Web of Science ®Google Scholar
• Fiyouzi T, Reche PA. Vaccine design: an introduction. Methods Mol Biol. 2023;2673:1–14. doi: 10.1007/978-1-0716-3239-0_1
   PubMedGoogle Scholar
• Sun B, Zhang Y. Overview of orchestration of CD4+ T cell subsets in immune responses. Adv Exp Med Biol. 2014;841:1–13. doi: 10.1007/978-94-017-9487-9_1
   PubMed Web of Science ®Google Scholar
• Niess JH, Adler G. Enteric flora expands gut lamina propria CX3CR1+ dendritic cells supporting inflammatory immune responses under normal and inflammatory conditions. J Immunol. 2010;184(4):2026–2037. doi: 10.4049/jimmunol.0901936
   PubMed Web of Science ®Google Scholar
• Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009;2(5):403–411. doi: 10.1038/mi.2009.100
   PubMed Web of Science ®Google Scholar
• Jaffar Z, Ferrini ME, Herritt LA, et al. Cutting edge: lung mucosal Th17-mediated responses induce polymeric ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol. 2009;182(8):4507–4511. doi: 10.4049/jimmunol.0900237
   PubMed Web of Science ®Google Scholar
• Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of T(H)17 cells. Nature. 2008;453(7198):1051–1057. doi: 10.1038/nature07036
   PubMed Web of Science ®Google Scholar
• Liang Y, Pan HF, Ye DQ. Tc17 cells in immunity and systemic autoimmunity. Int Rev Immunol. 2015;34(4):318–331. doi: 10.3109/08830185.2014.954698
   PubMed Web of Science ®Google Scholar
• Nanjappa SG, Heninger E, Wuthrich M, et al. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLOS Pathog. 2012;8(7):e1002771. doi: 10.1371/journal.ppat.1002771
   PubMed Web of Science ®Google Scholar
• Nanjappa SG, Hernandez-Santos N, Galles K, et al. Intrinsic MyD88-Akt1-mTOR signaling coordinates disparate Tc17 and Tc1 responses during vaccine immunity against fungal pneumonia. PLOS Pathog. 2015;11(9):e1005161. doi: 10.1371/journal.ppat.1005161
   PubMed Web of Science ®Google Scholar
• Mudalagiriyappa S, Sharma J, Vieson MD, et al. GM-CSF(+) Tc17 cells are required to bolster vaccine immunity against lethal fungal pneumonia without causing overt pathology. Cell Rep. 2022;41(4):111543. doi: 10.1016/j.celrep.2022.111543
   PubMed Web of Science ®Google Scholar
• Bielinska AU, Gerber M, Blanco LP, et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol. 2010;30(2):189–199. doi: 10.1615/critrevimmunol.v30.i2.60
   PubMed Web of Science ®Google Scholar
• Hirahara K, Kokubo K, Aoki A, et al. The role of CD4(+) resident memory T cells in local immunity in the mucosal tissue - protection versus pathology. Front Immunol. 2021;12:616309. doi: 10.3389/fimmu.2021.616309
   PubMed Web of Science ®Google Scholar
• Lin R, Zhang H, Yuan Y, et al. Fatty acid oxidation controls CD8(+) tissue-resident memory T-cell Survival in gastric adenocarcinoma. Cancer Immunol Res. 2020;8(4):479–492. doi: 10.1158/2326-6066.CIR-19-0702
   PubMed Web of Science ®Google Scholar
• de Vries, NL, van Unen V, Ijsselsteijn ME, et al. High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. Gut. 2020;69(4):691–703. doi: 10.1136/gutjnl-2019-318672
   PubMed Web of Science ®Google Scholar
• Buggert M, Nguyen S, Salgado-Montes de Oca G, et al. Identification and characterization of HIV-specific resident memory CD8(+) T cells in human lymphoid tissue. Sci Immunol. 2018;3(24): doi: 10.1126/sciimmunol.aar4526
   PubMed Web of Science ®Google Scholar
• Smith NM, Wasserman GA, Coleman FT, et al. Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia. Mucosal Immunol. 2018;11(1):220–235. doi: 10.1038/mi.2017.43
   PubMed Web of Science ®Google Scholar
• Ogongo P, Porterfield JZ, Leslie A. Lung tissue resident memory T-Cells in the immune response to mycobacterium tuberculosis. Front Immunol. 2019;10:992. doi: 10.3389/fimmu.2019.00992
   PubMed Web of Science ®Google Scholar
• Szabo PA, Dogra P, Gray JI, et al. Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis. medRxiv. 2020. doi: 10.1101/2020.10.15.20208041
   Google Scholar
• Iijima N, Iwasaki A. T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science. 2014;346(6205):93–98. doi: 10.1126/science.1257530
   PubMed Web of Science ®Google Scholar
• O’Hara JM, Redhu NS, Cheung E, et al. Generation of protective pneumococcal-specific nasal resident memory CD4(+) T cells via parenteral immunization. Mucosal Immunol. 2020;13(1):172–182. doi: 10.1038/s41385-019-0218-5
   PubMed Web of Science ®Google Scholar
• Zens KD, Chen JK, Farber DL. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight. 2016;1(10). doi: 10.1172/jci.insight.85832
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhao J, Mangalam AK, et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity. 2016;44(6):1379–1391. doi: 10.1016/j.immuni.2016.05.006
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi: 10.1038/s41577-020-00479-7
   PubMed Web of Science ®Google Scholar
• Squier CA, Mantz MJ, Schlievert PM, et al. Porcine vagina ex vivo as a model for studying permeability and pathogenesis in mucosa. J Pharm Sci. 2008;97(1):9–21. doi: 10.1002/jps.21077
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–384. doi: 10.1038/ni.1863
   PubMed Web of Science ®Google Scholar
• van Egmond M, Damen CA, van Spriel AB, et al. IgA and the IgA fc receptor. Trends Immunol. 2001;22(4):205–211. doi: 10.1016/s1471-4906(01)01873-7
   PubMed Web of Science ®Google Scholar
• Bruder MC, Spanhaak S, Bruijntjes JP, et al. Intestinal T lymphocytes of different rat strains in immunotoxicity. Toxicol Pathol. 1999;27(2):171–179. doi: 10.1177/019262339902700204
   PubMed Web of Science ®Google Scholar
• Church JA, Parker EP, Kirkpatrick BD, et al. Interventions to improve oral vaccine performance: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(2):203–214. doi: 10.1016/S1473-3099(18)30602-9
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. The influence of probiotics on vaccine responses - a systematic review. Vaccine. 2018;36(2):207–213. doi: 10.1016/j.vaccine.2017.08.069
   PubMed Web of Science ®Google Scholar
• Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol Rev. 2005;206(1):64–82. doi: 10.1111/j.0105-2896.2005.00290.x
   PubMedGoogle Scholar
• Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005;206(1):260–276. doi: 10.1111/j.0105-2896.2005.00291.x
   PubMedGoogle Scholar
• Lajeunesse M, Zhang Q, Finn A. Mucosal immunity to infections and its importance in future vaccinology. Adv Exp Med Biol. 2004;549:13–22. doi: 10.1007/978-1-4419-8993-2_4
   PubMed Web of Science ®Google Scholar
• Thwaites RS, Jarvis HC, Singh N, et al. Absorption of nasal and bronchial fluids: precision sampling of the human respiratory mucosa and laboratory processing of samples. J Vis Exp. 2018;(131). doi: 10.3791/56413
   PubMed Web of Science ®Google Scholar
• Wolsk HM, Chawes BL, Thorsen J, et al. Noninvasive sampling of mucosal lining fluid for the quantification of in vivo upper airway immune-mediator levels. J Vis Exp. 2017;(126). doi: 10.3791/55800
   PubMed Web of Science ®Google Scholar
• Holmgren J, Parashar UD, Plotkin S, et al. Correlates of protection for enteric vaccines. Vaccine. 2017;35(26):3355–3363. doi: 10.1016/j.vaccine.2017.05.005
   PubMed Web of Science ®Google Scholar
• Aase A, Sommerfelt H, Petersen LB, et al. Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction. Mucosal Immunol. 2016;9(4):884–893. doi: 10.1038/mi.2015.107
   PubMed Web of Science ®Google Scholar
• Ahren C, Jertborn M, Svennerholm AM. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin a responses in blood. Infect Immun. 1998;66(7):3311–3316. doi: 10.1128/IAI.66.7.3311-3316.1998
   PubMed Web of Science ®Google Scholar
• Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol. 1996;44(1–3):217–224. doi: 10.1016/0168-1656(95)00134-4
   PubMed Web of Science ®Google Scholar
• Saletti G, Cuburu N, Yang JS, et al. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat Protoc. 2013;8(6):1073–1087. doi: 10.1038/nprot.2013.058
   PubMed Web of Science ®Google Scholar
• Chang HS, Sack DA. Development of a novel in vitro assay (ALS assay) for evaluation of vaccine-induced antibody secretion from circulating mucosal lymphocytes. Clin Diagn Lab Immunol. 2001;8(3):482–488. doi: 10.1128/CDLI.8.3.482-488.2001
   PubMedGoogle Scholar
• Anosova NG, Chabot S, Shreedhar V, et al. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer’s patches. Mucosal Immunol. 2008;1(1):59–67. doi: 10.1038/mi.2007.7
   PubMed Web of Science ®Google Scholar
• Liang S, Hajishengallis G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol Invest. 2010;39(4–5):449–467. doi: 10.3109/08820130903563998
   PubMed Web of Science ®Google Scholar
• Fukuyama Y, Okada K, Yamaguchi M, et al. Nasal administration of cholera toxin as a mucosal adjuvant damages the olfactory system in mice. PLoS One. 2015;10(9):e0139368. doi: 10.1371/journal.pone.0139368
   PubMed Web of Science ®Google Scholar
• Levine MM, Kaper JB, Black RE, et al. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev. 1983;47(4):510–550. doi: 10.1128/mr.47.4.510-550.1983
   PubMedGoogle Scholar
• Freytag LC, Clements JD. Bacterial toxins as mucosal adjuvants. Curr Top Microbiol Immunol. 1999;236:215–236. doi: 10.1007/978-3-642-59951-4_11
   PubMed Web of Science ®Google Scholar
• Pizza M, Giuliani MM, Fontana MR, et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine. 2001;19(17–19):2534–2541. doi: 10.1016/s0264-410x(00)00553-3
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine. 2005;23(15):1804–1813. doi: 10.1016/j.vaccine.2004.11.010
   PubMed Web of Science ®Google Scholar
• van Ginkel, FW, Jackson RJ, Yoshino N, et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun. 2005;73(10):6892–6902. doi: 10.1128/IAI.73.10.6892-6902.2005
   PubMed Web of Science ®Google Scholar
• Mori I, Komatsu T, Takeuchi K, et al. Parainfluenza virus type 1 infects olfactory neurons and establishes long-term persistence in the nerve tissue. J Gen Virol. 1995;76(Pt 5):1251–1254. doi: 10.1099/0022-1317-76-5-1251
   PubMedGoogle Scholar
• van den Brand JM, Stittelaar KJ, van Amerongen G, et al. Comparison of temporal and spatial dynamics of seasonal H3N2, pandemic H1N1 and highly pathogenic avian influenza H5N1 virus infections in ferrets. PLoS One. 2012;7(8):e42343. doi: 10.1371/journal.pone.0042343
   PubMed Web of Science ®Google Scholar
• Cheng Q, Yang Y, Gao J. Infectivity of human coronavirus in the brain. EBioMedicine. 2020;56:102799. doi: 10.1016/j.ebiom.2020.102799
   PubMed Web of Science ®Google Scholar
• Huang J, Zheng M, Tang X, et al. Potential of SARS-CoV-2 to cause CNS infection: biologic fundamental and clinical experience. Front Neurol. 2020;11:659. doi: 10.3389/fneur.2020.00659
   PubMed Web of Science ®Google Scholar
• van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol. 2015;235(2):277–287. doi: 10.1002/path.4461
   PubMed Web of Science ®Google Scholar
• Jerusalmi A, Morris-Downes MM, Sheahan BJ, et al. Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther. 2003;8(6):886–894. doi: 10.1016/j.ymthe.2003.09.010
   PubMed Web of Science ®Google Scholar
• Kong IG, Sato A, Yuki Y, et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by streptococcus pneumoniae. Infect Immun. 2013;81(5):1625–1634. doi: 10.1128/IAI.00240-13
   PubMed Web of Science ®Google Scholar
• Fukuyama Y, Yuki Y, Katakai Y, et al. Nanogel-based pneumococcal surface protein a nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against streptococcus pneumoniae in macaques. Mucosal Immunol. 2015;8(5):1144–1153. doi: 10.1038/mi.2015.5
   PubMed Web of Science ®Google Scholar